Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K+-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure

Fig. 1

Study flow chart. Flow chart demonstrating design of the study. ACEi = ACE inhibitor, ARB = angiotensin receptor blocker, eGFR = estimated glomerular filtration rate, HFrEF = heart failure with reduced ejection fraction, MRA = mineralocorticoid receptor antagonist, OD = once daily, QOL = quality of life, SBP = systolic blood pressure, TDS = three times daily

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us